![]() | |
Names | |
---|---|
Preferred IUPAC name
5-[2,4-Dihydroxy-5-(propan-2-yl)phenyl]-N-ethyl-4-{4-[(morpholin-4-yl)methyl]phenyl}-1,2-oxazole-3-carboxamide | |
Other names
NVP-AUY-922; AUY922; VER-52296 | |
Identifiers | |
3D model (JSmol) |
|
ChEBI | |
ChEMBL | |
ChemSpider |
|
DrugBank | |
KEGG |
|
PubChem CID |
|
UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
Properties | |
C26H31N3O5 | |
Molar mass | 465.550 g·mol−1 |
Appearance | Colorless solid[1] |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Luminespib (INN,[2] previously known as NVP-AUY922) is an experimental drug candidate for the treatment of cancer. It was discovered through a collaboration between The Institute of Cancer Research and the pharmaceutical company Vernalis[3] and licensed to Novartis.[4] From 2011 to 2014 it was in Phase II clinical trials.[5][6] Chemically it is a resorcinylic isoxazole amide[6]
Luminespib is an inhibitorofheat shock protein 90 (Hsp90),[1] which is a chaperone protein that plays a role in the modification of a variety of proteins that have been implicated in oncogenesis. Luminespib has shown promising activity in preclinical testing against several different tumor types.[7][8][9][10]
A related compound, NVP-HSP990, was abandoned by Novartis in 2012 after it failed to show efficacy in an early clinical trial.[6]
![]() | This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |